| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Monday, February 07, 2022 2:38:10 PM
Please provide links to the videos of the ASM at a few microcap companies you actually invest in prior to 2019.
Post pandemic everyone has moved to virtual meetings, at least while the pandemic lasts. I am not talking about Berkshire Hathaway. None of the companies I have been in has ever provided actual transcripts of what was said at their ASM’s. Quarterly calls, yes, that is done by third parties generally.
It is not a common practice. You may misremember that it was, but it was not a common practice for small biotechs and NONE of the companies I have ever invested in, including some fairly large ones in this sector, provided either transcripts or video or access by video to their annual meetings. They did often summarize the business and proxy results. That’s it.
There is no rule against it, it’s just was a broadly observed practice not to do that. I would be hesitant to say how broad, but I’ve not seen it done generally, and certainly not prior to the pandemic, when ASM as a rule became virtual and open access, which changed the rules substantially from before.
Post pandemic everyone has moved to virtual meetings, at least while the pandemic lasts. I am not talking about Berkshire Hathaway. None of the companies I have been in has ever provided actual transcripts of what was said at their ASM’s. Quarterly calls, yes, that is done by third parties generally.
It is not a common practice. You may misremember that it was, but it was not a common practice for small biotechs and NONE of the companies I have ever invested in, including some fairly large ones in this sector, provided either transcripts or video or access by video to their annual meetings. They did often summarize the business and proxy results. That’s it.
There is no rule against it, it’s just was a broadly observed practice not to do that. I would be hesitant to say how broad, but I’ve not seen it done generally, and certainly not prior to the pandemic, when ASM as a rule became virtual and open access, which changed the rules substantially from before.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
